RxDoctor Payments Data

Salvatore Calandra, MD

Internal Medicine · East Amherst, NYNPI 1659307528

Payments from drug & device makers

$13,735in general payments, 2019–2025

Across 342 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7K
  • Boston Scientific$1K
  • Amgen$479
  • Johnson & Johnson$469
  • Cvrx, Inc.$446
  • Biotronik Inc.$359
  • plus $3K from 28 others

What the payments were for

  • Speaking & faculty fees$6,60048%
  • Food & beverage$6,99751%
  • Education$1381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,735 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$142,612
Medicare patients
386
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$103,974
XareltoRivaroxaban44$50,882
EntrestoSacubitril/Valsartan27$32,036
Metoprolol Succinate170$3,181
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$1,487
Digoxin30$967
Rosuvastatin Calcium76$862
Potassium Chloride48$752
Atorvastatin Calcium39$545
Dilt-XrDiltiazem Hcl25$544
Ezetimibe24$475
Amlodipine Besylate71$454
ClopidogrelClopidogrel Bisulfate30$444
Furosemide94$440
Flecainide Acetate14$397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$103,97499 claims
Johnson & JohnsonXarelto$469$50,88244 claims
NovartisEntresto$7,216$32,03627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →